Anzeige
Meldung des Tages: Gold im Fokus: Warum diese milliardenschwere Goldaktie vom aktuellen Goldumfeld profitieren könnte

Enliven Therapeutics Aktie News

Aktie
WKN:  ISIN:  US29337E1029 US-Symbol:  ELVN Branche:  Biotechnologie Land:  USA
27,02 $
-0,80 $
-2,88%
22,948 € 05.02.26
Depot/Watchlist
Marktkapitalisierung *
572,56 Mio. €
Streubesitz
-
KGV
-7,93
Index-Zuordnung
-

Enliven Therapeutics News

08.01.26 - PR Newswire
Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones
Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones PR Newswire
07.01.26 - PR Newswire
Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development
Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development PR Newswire
11.12.25 - PR Newswire
Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules PR Newswire
11.12.25 - PR Newswire
Enliven Therapeutics Announces New CEO to Drive Next Phase of Development
Enliven Therapeutics Announces New CEO to Drive Next Phase of Development PR Newswire
12.11.25 - PR Newswire
/C O R R E C T I O N -- Enliven Therapeutics, Inc./
/C O R R E C T I O N -- Enliven Therapeutics, Inc./ PR Newswire
25.08.25 - PR Newswire
Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2025 Annual Meeting
Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2025 Annual Meeting PR Newswire
13.08.25 - PR Newswire
Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update
Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update PR Newswire
16.06.25 - PR Newswire
Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares
Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-​Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares ...
13.06.25 - PR Newswire
Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-​Funded Warrants PR Newswire
13.06.25 - PR Newswire
Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-​Funded Warrants PR Newswire
13.06.25 - PR Newswire
Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress
Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress PR Newswire
22.05.25 - PR Newswire
Enliven Therapeutics to Present at Upcoming Investor Conferences
Enliven Therapeutics to Present at Upcoming Investor Conferences PR Newswire
14.05.25 - PR Newswire
Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress
Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress PR Newswire
02.04.25 - PR Newswire
Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting
Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting PR Newswire
13.03.25 - PR Newswire
Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update PR Newswire

Newssuche

Videos

newspaper
05.02.26 +8,47%
Technical Trading: Pfund Short im Februar
GBP/USD Short Typ: Turbo Open End WKN: VH3A2E Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »